Atlas Legacy Advisors LLC Takes Position in Stryker Co. (NYSE:SYK)

Atlas Legacy Advisors LLC bought a new position in Stryker Co. (NYSE:SYK - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 2,158 shares of the medical technology company's stock, valued at approximately $777,000.

Other large investors have also recently modified their holdings of the company. Parnassus Investments LLC bought a new position in Stryker during the third quarter valued at $762,798,000. International Assets Investment Management LLC grew its holdings in Stryker by 66,967.5% during the 3rd quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company's stock valued at $308,433,000 after purchasing an additional 852,496 shares during the last quarter. RTW Investments LP purchased a new stake in Stryker in the 3rd quarter worth about $143,392,000. State Street Corp lifted its stake in Stryker by 2.2% in the third quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock worth $5,279,788,000 after purchasing an additional 316,404 shares during the last quarter. Finally, FMR LLC grew its stake in shares of Stryker by 3.0% during the third quarter. FMR LLC now owns 7,306,994 shares of the medical technology company's stock valued at $2,639,725,000 after buying an additional 215,782 shares during the last quarter. Institutional investors own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

SYK has been the subject of a number of research analyst reports. The Goldman Sachs Group raised their price target on Stryker from $384.00 to $427.00 and gave the stock a "neutral" rating in a research note on Thursday, January 30th. Citigroup boosted their target price on shares of Stryker from $411.00 to $450.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Needham & Company LLC restated a "buy" rating and issued a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. Morgan Stanley upgraded shares of Stryker from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Finally, StockNews.com downgraded shares of Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, January 30th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $420.68.

Stryker Stock Down 1.0 %

SYK stock traded down $3.82 during trading on Friday, reaching $382.59. 1,268,413 shares of the company traded hands, compared to its average volume of 1,388,856. The company has a market capitalization of $145.99 billion, a price-to-earnings ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The business has a 50 day simple moving average of $377.92 and a 200 day simple moving average of $368.21. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company posted $3.46 EPS. On average, equities research analysts anticipate that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. Stryker's payout ratio is 43.30%.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.